JP2001106635A - Anti-rotavirus agent - Google Patents

Anti-rotavirus agent

Info

Publication number
JP2001106635A
JP2001106635A JP28745399A JP28745399A JP2001106635A JP 2001106635 A JP2001106635 A JP 2001106635A JP 28745399 A JP28745399 A JP 28745399A JP 28745399 A JP28745399 A JP 28745399A JP 2001106635 A JP2001106635 A JP 2001106635A
Authority
JP
Japan
Prior art keywords
rotavirus
extract
stevia
water
eluting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP28745399A
Other languages
Japanese (ja)
Inventor
Kazuo Takahashi
和郎 高橋
Shiro Shigeta
士郎 茂田
Naohiko Sato
直彦 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP28745399A priority Critical patent/JP2001106635A/en
Publication of JP2001106635A publication Critical patent/JP2001106635A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain an anti-rotavirus active substance which is derived from a natural product and hardly exhibits adverse drug reactions and to prevent or treat infectious diseases of human infants and infants of animals for industrial use, pets or the like. SOLUTION: The extract from stevia plant bodies, mainly stems and leaves, inhibits the adhesion or invasion of rotavirus into the cell and exhibits resistance to gastric acid. The active ingredient contained in the extract is present in a fraction obtained by eluting the extract with water by the use of ODS column and then eluting the resultant eluate with 20-70% ethanol. The ingredient is an acidic polysaccharide with a molecular weight of 20,000-80,000.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明が属する技術分野】本発明は、ステビアの葉及び
茎の熱水抽出物からなる抗ロタウイルス剤に関する。
The present invention relates to an anti-rotavirus agent comprising a hot water extract of stevia leaves and stems.

【0002】[0002]

【従来の技術】大部分のヒト(約90%)が乳幼児期に
ロタウイルスに感染し、嘔吐、下痢、発熱などの症状を
呈し、感染者の5〜10%は脱水症状のため入院治療を
要する。日本ではヒトの死亡率は非常に低いと思われる
が、猿、馬、豚、牛、鶏、犬、猫、兎、ねずみ等、多く
の産業動物やペットなどの動物が乳幼児期に感染し、こ
れら動物が感染した場合には死亡率も高く産業上の損失
も大きい。
2. Description of the Related Art Most humans (about 90%) are infected with rotavirus in infancy and exhibit symptoms such as vomiting, diarrhea and fever, and 5 to 10% of infected persons are hospitalized for dehydration. It costs. Although the human mortality rate is considered to be very low in Japan, many industrial animals and pets such as monkeys, horses, pigs, cattle, chickens, dogs, cats, rabbits, rats, etc. become infected during infancy, When these animals become infected, mortality is high and industrial losses are high.

【0003】[0003]

【発明が解決しようとする課題】1998年に米国では
弱毒性生ワクチンが承認されたが、治療法は対症療法で
あり、未だ有効な原因療法は開発されていない。本発明
は天然物由来で、一般の健康人も健康増進のために服用
している食品に由来する抗ロタウイルス剤を提供するこ
とを目的とする。
Although a live attenuated vaccine was approved in the United States in 1998, the treatment was symptomatic, and no effective causal therapy has yet been developed. An object of the present invention is to provide an anti-rotavirus agent derived from food products that are derived from natural products and are also taken by general healthy people for health promotion.

【0004】[0004]

【課題を解決するための手段】本発明は、ステビアの植
物体、主として茎及び葉の抽出液の220倍希釈液がロ
タウイルスの増殖を50%阻害する事実を見出して完成
したものである。抗ロタウイルス活性は、ステビアの抽
出原液及びODSカラムを用いて水で溶出後、20〜7
0%エタノールで溶出される分画中に認められ、酸性多
糖類である。このことからロタウイルスが細胞に感染す
る時にステビア抽出液中の有効成分がウイルスに結合し
て感染を阻止するものと推測される。
The present invention has been completed by finding out that a 220-fold diluted solution of Stevia plant, mainly stem and leaf extracts, inhibits the growth of rotavirus by 50%. The anti-rotavirus activity was determined to be 20 to 7 after elution with water using Stevia extract stock solution and ODS column.
It is found in the fraction eluted with 0% ethanol and is an acidic polysaccharide. This suggests that when rotavirus infects cells, the active ingredient in the stevia extract binds to the virus and inhibits infection.

【0005】本発明者らは抗ロタウイルス活性を有する
物質を求めて、各種物質をスクリーニングしてきたが、
健康飲料として服用されているステビア抽出液、特にこ
の溶液をYNMC−ODS逆層カラムクロマトグラフィ
ーにより水を抽出液として分画し、次いで30%エタノ
ール、次いで60%エタノールで溶出した溶出液が強い
抗ロタウイルス活性を有することを見出して本発明を完
成したものである。本発明の物質はロタウイルスに対し
て選択的に有効であり、インフルエンザやヘルペス等の
ウイルスに対しては効果を有しない。
[0005] The present inventors have screened various substances in search of substances having anti-rotavirus activity.
Stevia extract taken as a health drink, especially this solution is fractionated with water as an extract by YNMC-ODS reverse phase column chromatography, then eluted with 30% ethanol and then 60% ethanol. The present invention has been completed by finding that it has rotavirus activity. The substance of the present invention is selectively effective against rotavirus and has no effect on viruses such as influenza and herpes.

【0006】[0006]

【発明の実施の形態】本発明の原料となるステビアと
は、南米原産のキク科の多年生植物、ステビア・レバウ
ディアナ・ベルトニ(Stevia rebaudiana Bertoni )及
びその類縁植物である。実験の結果、有効成分は葉及び
茎、特に蕾を持つ前の茎や成熟した植物の茎に多く含有
されるが、根にも、花にも、幼弱植物にも有効成分が含
有されることを確認した。また、ステビアの甘味成分と
して知られるステビオサイドやレバディオサイドには抗
ロタウイルス活性が認められなかった。したがって、本
発明はステビアの植物組織全体の抽出物が含有されてい
ればよく、他の物質と配合されていても差支えない。
BEST MODE FOR CARRYING OUT THE INVENTION Stevia, which is a raw material of the present invention, is a perennial plant of the family Asteraceae native to South America, Stevia rebaudiana Bertoni and related plants. As a result of the experiment, the active ingredient is contained abundantly in the leaves and stems, especially in the stem before having buds and in the stems of mature plants, but the active ingredient is contained in roots, flowers, and young plants It was confirmed. Stevioside and revadioside, which are known as sweet components of stevia, did not show anti-rotavirus activity. Therefore, the present invention only needs to contain the extract of the whole plant tissue of Stevia, and may be mixed with other substances.

【0007】抽出法は特に限定はなく、ステビアの植物
組織に含有される成分を溶出できればよく、熱水抽出、
冷水抽出、或いは低級アルコール等による抽出液も使用
できる。有効成分を特定することはできないが、親水性
物質と考えられるため、例えばメチルアルコール、エチ
ルアルコール、n−プロピルアルコール、i−プロピル
アルコール等の低級アルコールで抽出する。有効成分は
分子量2万〜8万の酸性多糖類であると推測される。
The extraction method is not particularly limited as long as the components contained in the plant tissue of Stevia can be eluted.
Extraction with cold water or extraction with a lower alcohol or the like can also be used. Although the active ingredient cannot be specified, it is considered to be a hydrophilic substance, and thus is extracted with lower alcohols such as methyl alcohol, ethyl alcohol, n-propyl alcohol, and i-propyl alcohol. The active ingredient is assumed to be an acidic polysaccharide having a molecular weight of 20,000 to 80,000.

【0008】抽出するにあたっては、葉のみを摘み取
り、或いは植物の地上部を刈り取り、乾燥し或いはその
まま微粉砕する。茎は固いため微粉砕に先立ち断裁して
もよい。有効成分の溶出を容易にするためには微粉砕す
ることが好ましい。抽出は熱水を用いて30分以上煮沸
する。場合によっては一回目の抽出工程で得られた抽出
水を分離した残滓を、新たな抽出用熱水に投入して再抽
出すると有効成分がほぼ完全に抽出される。また、微粉
末を常温の水に2〜3日浸漬した上清、30〜50℃の
水に3時間浸漬した上清にも充分に有効成分が溶出して
いる。ステビア抽出液は濃縮して固形物濃度15〜20
W/V%の抽出原液として使用する。一般にステビアの
微粉砕物1kgから0.3〜3リットルの抽出原液が得
られる。
For extraction, only the leaves are picked, or the aerial part of the plant is cut off, dried or finely ground as it is. Since the stem is hard, it may be cut before pulverization. In order to facilitate the elution of the active ingredient, it is preferable to carry out fine pulverization. The extraction is boiled with hot water for 30 minutes or more. In some cases, when the residue obtained by separating the extraction water obtained in the first extraction step is put into new hot water for extraction and re-extracted, the active ingredient is almost completely extracted. Also, the active ingredient is sufficiently eluted in the supernatant obtained by immersing the fine powder in water at room temperature for 2 to 3 days, and in the supernatant immersed in water at 30 to 50 ° C. for 3 hours. Stevia extract is concentrated to a solid concentration of 15-20.
Used as a stock solution of W / V%. Generally, 0.3 to 3 liters of an undiluted extract is obtained from 1 kg of finely divided stevia.

【0009】抗ロタウイルス活性の測定はウイルス感染
に伴う細胞死とその抑制を呈色反応として測定するMT
T法を用いて行った。すなわち、生きている細胞は黄色
のテトラゾリウムを還元して赤紫色のフォルマザンを生
成し、この赤紫色の強度を690nmと540nmの2
波長による吸光度で測定するものである。MTT法はウ
イルスの感染によって細胞の完全な死が起こる細胞系を
選び、適正な細胞濃度とロタウイルス濃度を選べば、ロ
タウイルスは37℃で5日間培養することにより全細胞
を死滅させテトラゾリウムを添加しても還元せず、黄色
のままである。すなわち、培養終了後テトラゾリウムを
添加しても発色しないウェルは、ロタウイルスにより或
いは薬剤の毒性により全細胞が死滅或いはほとんどの細
胞が死滅したウェルである。
[0009] The anti-rotavirus activity is measured by MT, which measures cell death and its inhibition associated with virus infection as a color reaction.
This was performed using the T method. That is, living cells reduce yellow tetrazolium to produce reddish purple formazan, and the reddish purple intensity is reduced to 2 at 690 nm and 540 nm.
It is measured by absorbance according to wavelength. The MTT method selects a cell line in which complete cell death occurs due to virus infection, and if an appropriate cell concentration and rotavirus concentration are selected, rotavirus is cultured at 37 ° C for 5 days to kill all cells and to remove tetrazolium. It does not reduce upon addition and remains yellow. That is, a well that does not develop color even after the addition of tetrazolium after completion of culture is a well in which all cells have died or most of the cells have died due to rotavirus or the toxicity of the drug.

【0010】多数のウェルが整列したプレートを用い抗
HIV活性を試験したい物質を5倍段階希釈を繰返し、
これらを順次配列したウェルに添加して培養し、有効希
釈濃度及び細胞毒性濃度を算出することができる。アッ
セイで使用するロタウイルス量は、本来増殖するべき細
胞量に対して、ウイルス感染して生き残った細胞数が1
0〜20%になるようなウイルス濃度を予め測定してお
き、毎回この量のウイルスを用いる。したがって、抗ウ
イルス薬のないウェルでも最大の10〜20%が生き残
っているようにアッセイされるのが良い条件である。
[0010] Using a plate in which a number of wells are aligned, a substance to be tested for anti-HIV activity is repeatedly subjected to 5-fold serial dilution.
These are sequentially added to wells arranged and cultured, and the effective dilution concentration and cytotoxic concentration can be calculated. The amount of rotavirus used in the assay is as follows: the number of cells surviving virus infection is one to the amount of cells that should originally grow.
The virus concentration is determined in advance so as to be 0 to 20%, and this amount of virus is used every time. Therefore, it is good conditions to assay so that a maximum of 10-20% survive in wells without antivirals.

【0011】[0011]

【実施例】ステビア試験液の製造 春にステビアの株苗を定植し、蕾を持つ前に地上部を刈
り取った。刈り取り後風乾して葉と茎とに分離した。葉
は粉砕機により10μm以下に粉砕しステビア葉粉末を
製造し、茎は5cmの大きさに切断後、粉砕機により1
0μm以下に粉砕しステビア茎粉末を製造した。かくし
て得られたステビア葉粉末とステビア茎粉末を、3:7
の割合に配合し均一に混合し、ステビア混合粉末の濃縮
原料とした。
EXAMPLES Preparation of Stevia Test Solution Stevia seedlings were planted in the spring and the above-ground parts were cut off before having buds. After cutting, it was air-dried and separated into leaves and stems. The leaves are pulverized to 10 μm or less by a pulverizer to produce stevia leaf powder, and the stem is cut to a size of 5 cm.
It was pulverized to 0 μm or less to produce Stevia stem powder. The stevia leaf powder and the stevia stem powder thus obtained were mixed in a ratio of 3: 7
And uniformly mixed to obtain a concentrated raw material of the mixed powder of Stevia.

【0012】ステビア混合粉末1kgに対し水10リッ
トルを用いて1時間煮沸した。冷却後絞り機により搾り
かすを分離し、3時間煮詰めて1.3リットルのステビ
ア抽出原液を得た。この抽出原液を容器に入れ常温で放
置したところ醗酵が進行して間欠的に炭酸ガスを放出す
る必要があった。醗酵は初期には激しく行われ、3〜4
か月経過すると次第に緩徐になるが、1年経過後、2〜
3年以上経過後も醗酵は継続した。本実施例において
は、半年醗酵させたステビア抽出原液を使用した。した
がって、本実施例におけるステビア液は、原料ステビア
混合粉末0.77g/cm3 に相当する。
1 kg of stevia mixed powder was boiled for 1 hour using 10 liters of water. After cooling, pomace was separated by a squeezing machine and boiled down for 3 hours to obtain 1.3 liters of a stevia extract stock solution. When this undiluted extract was put in a container and allowed to stand at room temperature, fermentation proceeded and it was necessary to intermittently release carbon dioxide. The fermentation is carried out violently in the beginning, 3-4
After a month, it gradually decreases, but after one year,
The fermentation continued after more than three years. In this example, a stevia extract stock solution fermented for half a year was used. Therefore, the stevia liquid in this example corresponds to 0.77 g / cm 3 of the raw material stevia mixed powder.

【0013】上記の方法で得られたステビアの原液を、
YNMC−ODS逆層カラムクロマトグラフィーにより
水を用いて分画し、初期に溶出した分画から順にフラク
ション1〜フラクション5とし、次いで30%メタノー
ル溶出液(フラクション6)、60%エタノール溶出液
(フラクション7)及び100%エタノール溶出液(フ
ラクション8)及び原液についてそれぞれ抗ロタウイル
ス活性をMTT細胞毒性分析法により測定した。原液、
30%エタノール溶出液及び60%エタノール溶出液に
抗ロタウイルス活性が確認された。
The stevia stock solution obtained by the above method is
Fractionation using YNMC-ODS reverse phase column chromatography using water, fractions 1 to 5 in order from the fraction eluted at the beginning, and then a 30% methanol eluate (fraction 6) and a 60% ethanol eluate (fraction) The anti-rotavirus activity of each of the 7) and 100% ethanol eluate (fraction 8) and the stock solution was measured by MTT cytotoxicity assay. Undiluted solution,
Anti-rotavirus activity was confirmed in the 30% ethanol eluate and the 60% ethanol eluate.

【0014】抗ロタウイルス活性試験 抗ロタウイルス活性はMTT法を用いて測定した。細胞
株はMA104株(アフリカミドリザルの細胞)を用
い、牛胎児血清(FCS)を10%含むように調整した
培地を用い、37℃、120時間、細胞の浮遊培養を行
った。ステビア抽出液は原液を用い5倍段階希釈法で希
釈を繰返して添加し、マイクロプレートを用いてこの培
養液に培養初期から100PFUのロタウイルスWa株
を接種し、薬剤無添加のウェルと薬剤添加ウェルを試験
し、薬剤有効濃度を測定した。培養終了後、テトラゾリ
ウム溶液を均等に添加し、フォルマザンの赤紫色の発色
を690nmと540nmの2波長による吸光度で測定
し、ウイルスに対する50%抑制濃度(EC50)と細胞
毒性濃度(CC50)を算出した。ステビア抽出液のEC
50は原液の220倍希釈液であり、CC50は105倍希
釈液であった。
Anti-rotavirus activity test Anti-rotavirus activity was measured using the MTT method. The cell line was MA104 strain (African green monkey cells), and cells were subjected to suspension culture at 37 ° C. for 120 hours using a medium adjusted to contain 10% fetal calf serum (FCS). Stevia extract was repeatedly added to the stock solution by a 5-fold serial dilution method, and the culture was inoculated with 100 PFU of rotavirus Wa strain from the beginning of culture using a microplate. Wells were tested to determine the effective drug concentration. After completion of the culture, the addition of the tetrazolium solution evenly, the color development of red purple formazan measured at absorbance two wavelengths 690nm and 540 nm, 50% inhibitory concentration against viruses (EC 50) and cytotoxic concentrations (CC 50) Calculated. EC of stevia extract
50 was a 220-fold dilution of the stock solution, and CC 50 was a 105-fold dilution.

【0015】ヒト及び動物への応用を考慮すると、胃酸
により失活してはならない。そこで、塩酸を加えてpH
2に調整して30分間放置した後、中和して抗ロタウイ
ルス活性を測定したが、ロタウイルス活性の低下は観察
されなかった。
For human and animal applications, it must not be inactivated by stomach acid. Therefore, add hydrochloric acid to adjust pH
After being adjusted to 2 and allowed to stand for 30 minutes, neutralization was performed and anti-rotavirus activity was measured, but no decrease in rotavirus activity was observed.

【0016】[0016]

【発明の効果】本発明による抗ロタウイルス活性物質は
副作用がほとんどなく、従来からヒト及び動物に服用さ
れてきたものであるため、ヒト、産業動物、ペット等の
ロタウイルスの罹患や死亡を防止するために安心して使
用することができる。
EFFECT OF THE INVENTION Since the anti-rotavirus active substance according to the present invention has almost no side effects and has been conventionally taken by humans and animals, it prevents the morbidity and death of rotavirus in humans, industrial animals and pets. Can be used with confidence.

───────────────────────────────────────────────────── フロントページの続き Fターム(参考) 4C086 AA01 AA02 EA24 GA17 MA01 MA04 NA14 ZA71 ZB33 4C088 AB26 AC05 BA09 CA05 CA06 CA14 CA25 MA52 NA14 ZA71 ZB33  ──────────────────────────────────────────────────続 き Continued on the front page F term (reference) 4C086 AA01 AA02 EA24 GA17 MA01 MA04 NA14 ZA71 ZB33 4C088 AB26 AC05 BA09 CA05 CA06 CA14 CA25 MA52 NA14 ZA71 ZB33

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 ステビアの植物体の抽出液を含有し、ロ
タウイルスの動物細胞への侵入を阻害する抗ロタウイル
ス剤。
1. An anti-rotavirus agent comprising an extract of a Stevia plant and inhibiting the entry of rotavirus into animal cells.
【請求項2】 ステビアの植物体の抽出液中、ODSカ
ラムを用いて水で溶出後、20〜70%エタノールで溶
出される分画中に存在する請求項1記載の抗ロタウイル
ス剤。
2. The anti-rotavirus agent according to claim 1, which is present in a stevia plant extract in a fraction eluted with 20-70% ethanol after elution with water using an ODS column.
【請求項3】 分子量2万〜8万の酸性多糖類であるこ
とを特徴とする請求項1又は2記載の抗ロタウイルス
剤。
3. The anti-rotavirus agent according to claim 1, which is an acidic polysaccharide having a molecular weight of 20,000 to 80,000.
JP28745399A 1999-10-08 1999-10-08 Anti-rotavirus agent Pending JP2001106635A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP28745399A JP2001106635A (en) 1999-10-08 1999-10-08 Anti-rotavirus agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28745399A JP2001106635A (en) 1999-10-08 1999-10-08 Anti-rotavirus agent

Publications (1)

Publication Number Publication Date
JP2001106635A true JP2001106635A (en) 2001-04-17

Family

ID=17717538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP28745399A Pending JP2001106635A (en) 1999-10-08 1999-10-08 Anti-rotavirus agent

Country Status (1)

Country Link
JP (1) JP2001106635A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984170A (en) * 2015-08-10 2015-10-21 庄立 Application of traditional Chinese medicine composite in treating rabies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984170A (en) * 2015-08-10 2015-10-21 庄立 Application of traditional Chinese medicine composite in treating rabies

Similar Documents

Publication Publication Date Title
Street et al. Cichorium intybus: Traditional uses, phytochemistry, pharmacology, and toxicology
Erhirhie et al. Medicinal values on Citrullus lanatus (watermelon): pharmacological review
Dixit et al. Medicinal properties of Moringa oleifera: A review
US20220096588A1 (en) Synergistic composition for osteoarthritis
Mahmud A review: medicinal values, agronomic practices and postharvest handlings of Vernonia amygdalina
Panda et al. Therapeutic potential of Bauhinia racemosa-a mini review
KR101807800B1 (en) Additives for stock feed comprising
KR100920713B1 (en) A composition for the treatment or prevention of diarrhea
US20030026859A1 (en) Antiviral composition derived from Allium cepa and therapeutic use thereof
Singh et al. Phytochemistry and medicinal uses of moringa oleifera: an overview
JP2001106635A (en) Anti-rotavirus agent
Kumari et al. “Erythrina variegata L.” The Coral Tree: A Review
Rana et al. The Various Pharmacological Activity of Adansonia digitata
KR100904859B1 (en) The healthy and funtional foods for the gastritis, stomach and duodenal ulcer patients using solanum tuberosum l., cv. bora valley
Aman et al. Pharmacological activities of Chenopodium album Linn—a review
Shirisha et al. Review on Albizia lebbeck (L.) Benth: a plant possessing diverse pharmacological activities
Lim Leucaena leucocephala
JPH10179157A (en) Chlorophyllase inhibitor, and food, feed and cosmetic containing the inhibitor
CN1909915B (en) Herbage composition for treating stomach intestinal tract disease
KR101800870B1 (en) Composition for improving livestock immunity comprising probiotics as effective component
Navya et al. Antimicrobial activities of Careya arborea: A review
Nair et al. Medicinal value of Bael, Aegle marmelos
Joshi et al. Vernonia amygdalina Delile-a promising anti-cancerous and ethnomedicinal shrub
Muhammad et al. Nigerian plants with anti-inflammatory and antifungal potential
KR20030088329A (en) Diabetes treatment substance extraction

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060208